Pliant Therapeutics (NASDAQ:PLRX) Announces Quarterly Earnings Results

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) posted its earnings results on Monday. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17, Zacks reports.

Pliant Therapeutics Trading Up 3.9 %

Shares of PLRX traded up $0.06 during mid-day trading on Thursday, reaching $1.58. 1,894,385 shares of the company's stock traded hands, compared to its average volume of 843,300. The stock has a market cap of $96.15 million, a P/E ratio of -0.47 and a beta of 1.18. The stock's 50-day moving average is $8.35 and its two-hundred day moving average is $11.59. Pliant Therapeutics has a 12 month low of $1.26 and a 12 month high of $16.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26.

Insider Activity

In related news, General Counsel Mike Ouimette sold 10,230 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total value of $112,427.70. Following the transaction, the general counsel now owns 70,544 shares of the company's stock, valued at $775,278.56. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Hans Hull sold 15,936 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the transaction, the insider now directly owns 211,558 shares in the company, valued at approximately $2,369,449.60. This trade represents a 7.01 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,855 shares of company stock valued at $1,026,628. 6.40% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PLRX. Leerink Partners downgraded Pliant Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $33.00 to $2.00 in a research report on Monday. Wells Fargo & Company decreased their price objective on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Citigroup decreased their price objective on Pliant Therapeutics from $4.00 to $1.50 and set a "neutral" rating on the stock in a research report on Tuesday. HC Wainwright restated a "neutral" rating on shares of Pliant Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC restated a "hold" rating and set a $10.00 price objective on shares of Pliant Therapeutics in a research report on Tuesday. Twelve investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $13.31.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.